Disease flares with baricitinib dose reductions and development of flare criteria in patients with CANDLE/PRAAS.

Kader Cetin GedikAna M Ortega-VillaGrace MaterneAndre RastegarGina A Montealegre SanchezAdam ReinhardtPaul A BroganYackov BerkunSara MuriasMaria RoblesSusanne SchalmAdriana A de JesusRaphaela Goldbach Mansky

Published in: Annals of the rheumatic diseases (2024)

We observed disease flares and rebound inflammation with baricitinib dose reductions and proposed flare criteria that can assist in monitoring disease activity and in designing clinical studies in CANDLE/PRAAS.

Keyphrases

disease activity
rheumatoid arthritis
systemic lupus erythematosus
rheumatoid arthritis patients
ankylosing spondylitis
oxidative stress
juvenile idiopathic arthritis